|
|
|
|
FDA Advisory Committee Unanimously Recommends OVATION Pharmaceuticals, Inc.'s Sabril(R) (vigabatrin) for the T
DEERFIELD, Ill.--(BUSINESS WIRE)-- announced today that the Peripheral and Central Nervous System Drugs Advisory Committee appointed by the U.S.Food and Drug Administration (FDA) voted unanimously (23-0) to recommend...
|
|
|
Advisors Recommend FDA Approval for Drug to Treat Seizure in Kids
ROCKVILLE, Md., Jan.9 -- An FDA advisory panel has unanimously recommended approval for the investigational anti-seizure drug vigabatrin (Sabril) for infantile spasms, despite evidence that the drug was associated loss of peripheral...
|
|
|
FDA Advisory Committee Unanimously Recommends Sabril (vigabatrin) for the Treatment of Two Catastrophic Epil
OVATION Pharmaceuticals, Inc.announced today that the Peripheral and Central Nervous System Drugs Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) voted unanimously (23-0) to recommend Sabril...
|
|
|
FDA Advisory Committee Unanimously Recommends Sabril (vigabatrin) for the Treatment of Two Catastrophic Epil
OVATION Pharmaceuticals, Inc.announced today that the Peripheral and Central Nervous System Drugs Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) voted unanimously (23-0) to recommend Sabril...
|
|
|
Aurobindo Pharma receives Health Canada approval for Capsules to treat Epilepsy
Aurobindo Pharma Limited is pleased to announce that it has received the approval for its Abbreviated New Drug Submission Gabapentin Capsules 100mg, 300mg and 400mg from Health Canada.Gabapentin Capsules 100mg, 300mg and 400mg is the...
|
|
|
FDA Panel Recommends Approval of Anti-Epilepsy Drug
ROCKVILLE, Jan.8 -- An investigational anti-seizure drug shown to cause irreversible vision loss should be approved in the United States, the FDA's advisory committee on neurology drugs recommended in a unanimous vote. The Peripheral...
|
|
|
FDA Panel to Vote on Investigational Epilepsy Drug for Kids and Adults
ROCKVILLE, Jan.6 -- The FDA's advisory committee on neurology drugs will decide this week whether to recommend approval of an investigational anti-seizure drug known to cause irreversible vision loss in a significant fraction of patients....
|
|
|
Aurobindo Pharma's Gabapentin Capsules receives approval from Health Canada
Aurobindo Pharma Limited is pleased to announce that it has received the approval for its Abbreviated New Drug Submission Gabapentin Capsules 100mg, 300mg and 400mg from Health Canada.Gabapentin Capsules 100mg, 300mg and 400mg is the...
|
|
|
Aurobindo's Gabapentin receives approval in Canada
Indian pharmaceutical company, Aurobindo has received approval from Health Canada for Gabapentin capsules, which is used for treating seizures in patients diagnosed with epilepsy.The Abbreviated New Drug submission was for 100mg, 300mg...
|
|
|
Autonomic Complications Following Central Nervous System Injury
Baguley IJ - This review presents a current understanding of each condition and suggests simple management protocols.With the marked disparity in the literature for the two conditions, the main focus is on the literature for dysautonomia....
|
|
|
[Review Articles] The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
General Description of Incretins A.Glucose-Dependent Insulinotropic Peptide B. Glucagon-Like Peptide-1 III. Synthesis, Secretion, and Degradation of Incretins A. Synthesis, Secretion, and Degradation of Glucose-Dependent...
|
|
|
Diffuse Hemangiomatosis With Predominant Central Nervous System Involvement
Al-Kaab A et al.- The early appearance of central nervous system lesions on imaging can overlap with that of cavernous malformations, confounding diagnosis; however, rapid growth, response to steroids, cystic appearance with...
|
|
|
Aurobindo Pharma receives 4 new registrations from MCC - South Africa
Aurobindo Pharma Ltd is pleased to announce that it has received registrations from the Medicines Control Council (MCC) to manufacture and market 4 products under the CNS (Central Nervous System) segment, in South Africa.
|
|
|
Newron Pharmaceuticals And Partners Awarded EUR 1 Million By Regione Lombardia For R&D On Innovative Nav 1.7 B
- Newron Pharmaceuticals S.p.(Newron), a research and development company focused on novel CNS and pain therapies, today announced that the company is participating in a consortium led by Axxam S.p. A that has been awarded a grant of...
|
|
|
Anti-Amnesic And Neuroprotective Effects Of Alzheimer's Compound Anavex 1-41 Published In Journal Of Neuropsyc
('ANAVEX') (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, announces that the anti-amnesic and...
|
|
|
Change in Newron Pharmaceuticals Group Management
- Newron Pharmaceuticals S.p.(Newron), a research and development company focused on novel CNS and pain therapies, today announced that Carlos de Sousa, a member of the companys management team and Chief Business Officer, has resigned for...
|
|
|
Ground-Breaking Anti-Amnesic and Neuroprotective Effects of Alzheimer's Compound Anavex 1-41 Published in Jour
-- Anavex Life Sciences Corp.(ANAVEX) (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, announces that...
|
|
|
Ground-Breaking Anti-Amnesic and Neuroprotective Effects of Alzheimer's Compound Anavex 1-41 Published in Jour
-- Anavex Life Sciences Corp.(ANAVEX) (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, announces that...
|
|
|
Workshop on intra-dermal rabies vaccination
HYDERABAD: A four-day workshop on 'Intra Dermal Rabies Vaccination - Training of Trainers (IDRV-TOT), being organised by the Institute of Preventive Medicine in collaboration with the health ministry of the Kerala Government, began here...
|
|
|
Diffusion-Weighted Imaging Findings in Hemolytic Uremic Syndrome With Central Nervous System Involvement
Toldo I et al.- The authors describe a 19-month-old child affected by hemolytic uremic syndrome with basal ganglia lesions documented by diffusion-weighted imaging, with a 42-day neuroradiological follow-up and a 6-month clinical follow...
|
|
|
Joern Aldag Resigns as CEO of Evotec AG (EVTG.F)
HAMBURG, Germany, Dec.10, 2008 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT.F - News) (NasdaqGM:EVTC - News) announced today that Joern Aldag will resign from his position as President & Chief Executive Officer of Evotec. The...
|
|
|
Anavex Presents Potent Neuroprotective Effects Of Anavex 1-41 At Neuroscience 2008
('ANAVEX') (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, was selected to present its latest results with...
|
|
|
Anavex Life Sciences Corp. (AVXL.OB) Presents Potent Neuroprotective Effects Of Anavex 1-41 At Neuroscience 20
-- (ANAVEX) (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, was selected to present its latest results...
|
|
|
Evotec Announces Three-Year Drug Discovery Collaboration
Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today announced the start of a research collaboration with Novartis to identify and develop novel small molecule therapeutics.The collaboration will run for an initial period of...
|
|
|
Neuralstem Collaborates with Hospital in Taiwan to Develop Additional ALS Stem Cell Clinical Trials
ROCKVILLE, Md., Dec.2 /PRNewswire-FirstCall/ -- Neuralstem Inc. (NYSE Alternext US: CUR) announced today that it has entered into a collaboration with the China Medical University & Hospital of Taiwan, to advance development of...
|
